ReviewMolecular therapy. Oncology2025
Translational drugs targeting cancer stem cells in triple-negative breast cancer.
Review in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Genome-wide association study reveals loci associated with cytokine levels in chicken serum.Poultry science · 2026Article
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential.Biomedicines · 2026Review
- Honokiol Suppresses Stemness and Sensitizes Triple-Negative Breast Cancer to Chemotherapy via YAP/TAZ-TEAD Inhibition.Oncology research · 2026Article
- Review
- Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors.Cell death & disease · 2025Review
- Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is unresponsive to targeted therapy and is associated with a high degree of malignancy, a high propensity for metastasis, high recurrence rates, and poor prognosis. In the modern concept of cancer biology, a subset of cancer cells known as tumor-initiating cells or cancer stem cells (CSCs) are defined as essential for the development and dissemination of cancer. These are a population of highly tumorigenic and self-renewing pluripotent cells that are inherently associated to the initiation, dissemination, relapse, and development of drug resistance. Specifically, some cell signaling pathways may affect the ability of CSCs to self-renew, differentiate, proliferate, and survive. To guide future research, in this review, we address compounds that target cell signaling and eliminate TNBC stem cells. Potential translational inhibitors of the Hedgehog, nuclear factor κB (NF-κB), Wnt, Notch, Hippo, TGF-β, JAK/STAT, and PI3K/AKT/mTOR cell signaling pathways are discussed, with a focus on TNBC stem cell eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.